STOCK TITAN
  1. Home
  2. News
  3. CYCN

Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that Company management will present at two upcoming investor conferences.

  • H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021. On-demand session is available starting at 7:00 a.m. EDT on September 13th.
  • Cantor Fitzgerald Virtual Global Healthcare Conference, September 30, 2021 at 2:40 p.m. EDT.

The live webcasts can be accessed via the Investors & Media section of the Cyclerion website at https://ir.cyclerion.com/news-events/event-calendar. An archived replay of the events will be available on the site for approximately 90 days following the presentations.

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next generation sGC stimulator.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

Media
Amanda Sellers
Verge Scientific Communications
asellers@vergescientific.com


Stock CYCN logo
Cyclerion Therapeutics, Inc.

NASDAQ:CYCN

CYCN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CYCN Latest News

Dec 4, 2023
Cyclerion Appoints Regina Graul, Ph.D., as President
Nov 30, 2023
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
Jul 31, 2023
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
Jun 1, 2023
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023
Cyclerion Announces Reverse Stock Split

CYCN Stock Data

7.64M
1.13M
20.77%
41.34%
0.81%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About CYCN

cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.